Stay updated on Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial

Sign up to get notified when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A site-wide notice regarding a lapse in government funding is displayed, stating information may not be up to date and transactions may not be processed. The page also shows a revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-02-04T10:21:16.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Editorial/metadata updates include showing the glossary, updating the QC criteria label, capitalization tweaks for FEAR Act data, and a new revision tag (v3.4.0), and these changes do not affect the core study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-28T06:14:44.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.3 to v3.3.4, a minor metadata/UI change. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T03:46:57.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The Study Locations section was updated with many new sites across the US, Canada, Argentina, France, Germany, Japan, Spain, and the UK, and several existing sites were removed. This expands and refines the recruitment footprint across multiple countries.
    Difference
    2%
    Check dated 2025-12-23T20:29:25.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    A new PubMed citation has been added to the Publications section: 'Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naive Patients with Chronic Spontaneous Urticaria' (Dermatol Ther (Heidelb), online ahead of print, 2025 Dec 2, doi:10.1007/s13555-025-01605-w). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-09T01:32:33.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Publications added to the Publications section include a 2025 article on dupilumab and CSU. The page also notes Revision: v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-24T21:01:42.000Z thumbnail image

Stay in the know with updates to Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.